pyrvinium
Trade name: povan
Pyrvinium (Viprynium) is an anthelmintic effective for pinworms. Pyrvinium is used in the treatment of enterobiasis caused by Enterobius vermicularis (pinworm). Pyrvinium has being shown to be a potent inhibitor of Wnt signaling (EC(50) of ∼10 nM). Pyrvinium binds all casein kinase 1 (CK1) family members in vitro at low nanomolar concentrations and pyrvinium selectively potentiates casein kinase 1α (CK1α) kinase activity. Pyrvinium pamoate (PP) is a potent noncompetitive inhibitor of the androgen receptor (AR). A noncompetitive AR inhibitor pyrvinium has significant potential to treat CRPC, including cancers driven by ligand-independent AR signaling. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 1 marketing orgs
Earliest trial started Jul 29, 2021 (NCT05055323)
Timeline
1950s
- Jun 1, 1956
Parke-Davis — First NDA Organization
- Jun 1, 1956
Parke-Davis — NDA Organization
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Unspecified targetOTHER
Unknown
Approval history
- approved—
Chemistry & pharmacology
SMILES
Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1- Mol. weight
- 382.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1201303 ↗
- WikipediaPyrvinium ↗
- NCATS6B9991FLU3 ↗
- ChEMBLCHEMBL1908377 ↗
Also known as
- 6-(dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl)-1-methylquinolinium
- molevac
- pamoxan
- poquil
- povan
- povan
- povan
- povanyl
- pyrcon
- pyrvinium
- pyrvinium
- pyrvinium
- pyrvinium
- pyrvinium
- pyrvinium
- pyrvinium
- pyrvinium
- pyrvinium embonate
- pyrvinium embonate
- pyrvinium iodide
- pyrvinium monohydroxide
- pyrvinium pamoate
- pyrvinium pamoate
- pyrvinium pamoate
- pyrvinium pamoate
- pyrvinium pamoate
- pyrvinium pamoate
- pyrvinium pamoate
- pyrvinium pamoate (2:1)
- vankin
- vanquil
- vanquil
- vanquin
- vanquin
- vanquin
- viprynium
- viprynium embonate
- viprynium embonate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05055323 | Phase 1 | Jul 29, 2021 | Thomas Jefferson University |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2021 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Parke-Davis | For profit | NDA | Jun 1, 1956 |